Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ALZN
ALZN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALZN News
Alzamend Neuro Completes Clinical Phase of Phase II Trial for AL001 "Lithium in Brain" at Massachusetts General Hospital
Nov 19 2025
Newsfilter
EXCLUSIVE: Alzamend Completes Clinical Phase of AL001 Study In Healthy Volunteers
Nov 19 2025
Benzinga
Hewlett Packard Enterprise Set to Surge by 33%? Check Out 10 Leading Analyst Predictions for Thursday
Aug 21 2025
Benzinga
Ascendiant Capital Reaffirms Buy Rating on Alzamend Neuro, Adjusts Price Target to $45
Aug 21 2025
Benzinga
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Jul 28 2025
Newsfilter
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Jun 16 2025
Newsfilter
Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone
May 29 2025
Benzinga
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results
May 29 2025
Benzinga
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
May 29 2025
TipRanks
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue
May 29 2025
Benzinga
Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update
May 29 2025
TipRanks
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital
May 29 2025
Newsfilter
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants
May 13 2025
Benzinga
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested
May 11 2025
TipRanks
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
May 07 2025
Newsfilter
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program
May 07 2025
Benzinga
Show More News
